Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
ARHGEF18 antisense RNA 1 (ARHGEF18-AS1) is a non-coding RNA transcript classified as an antisense long noncoding RNA (lncRNA)[1][3][6]. It is transcribed from the strand complementary to the ARHGEF18 gene, a known Rho/Rac guanine nucleotide exchange factor involved in actin cytoskeleton organization[1][4]. While the specific biological functions and disease roles of ARHGEF18-AS1 have not been experimentally delineated, antisense lncRNAs in general are important regulators of gene expression, often modulating the expression of their sense gene at transcriptional or post-transcriptional levels[3][6]. They are increasingly recognized for their roles in epigenetic modification and regulation of cellular processes, and their dysregulation can contribute to human diseases, especially cancers[3]. There are currently no known drugs targeting ARHGEF18-AS1 and it is not considered a therapeutic target in itself.
Not established for ARHGEF18-AS1; in general, antisense lncRNAs may: Interfere with the transcription or stability of the corresponding sense mRNA; Recruit epigenetic modifiers to gene loci
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on ARHGEF18 antisense RNA 1 (ARHGEF18-AS1).